MGC Pharmaceuticals has appointed Sciensus Rare as exclusive distributor of its CannEpil treatment, for refractory epilepsy, and CogniCann, for dementia and Alzheimer’s, in the UK, Denmark, France, Italy, Spain and Luxembourg.
For the initial 12 months of the four-year term, Sciensus Rare will be subject to minimum purchase order requirements to maintain its exclusive distributor status.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.